|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: darunavir ethanolate
Summary for Generic Name: darunavir ethanolate
| |||||||||||||||
Clinical Trials for: darunavir ethanolateA Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women Status: Recruiting Condition: HIV; HIV Infections; Pregnancy TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients Status: Completed Condition: HIV Infections An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients Status: Completed Condition: Human Immunodeficiency Virus (HIV) Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects Status: Completed Condition: HIV Infections TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV Status: Active, not recruiting Condition: HIV-1 Infections Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults Status: Active, not recruiting Condition: Acquired Immunodeficiency Syndrome; HIV Infections DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects Status: Recruiting Condition: HIV Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study Status: Active, not recruiting Condition: HIV Infections A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions Status: Completed Condition: Healthy Participants Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz Status: Active, not recruiting Condition: Hyperlipidemia; HIV Courtesy of ClinicalTrials.org See more clinical trials for this drug | |||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Patented / Exclusive Use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Prods | PREZISTA | darunavir ethanolate | TABLET; ORAL | 021976 | Nov 9, 2012 | RX | Yes | <disabled> | UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Janssen Prods | PREZISTA | darunavir ethanolate | TABLET; ORAL | 021976 | Nov 9, 2012 | RX | Yes | <disabled> | PEDIATRIC EXCLUSIVITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Janssen Prods | PREZISTA | darunavir ethanolate | TABLET; ORAL | 021976 | Nov 9, 2012 | RX | Yes | <disabled> | NEW PATIENT POPULATION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Janssen Prods | PREZISTA | darunavir ethanolate | TABLET; ORAL | 021976 | Nov 9, 2012 | RX | Yes | <disabled> | 800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNIVIR RESISTANCE ASSOCIATED SUBSITUTIONS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc